Ziogas Ioannis A, Tsoulfas Georgios
Ioannis A Ziogas, Aristotle University of Thessaloniki School of Medicine, 54124 Thessaloniki, Greece.
World J Clin Oncol. 2017 Jun 10;8(3):203-213. doi: 10.5306/wjco.v8.i3.203.
Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide and comes third in cancer-related mortality. Although there is a broad spectrum of treatment options to choose from, only a few patients are eligible candidates to receive a curative therapy according to their stage of disease, and thus palliative treatment is implemented in the majority of the patients suffering from liver cancer. Sorafenib, a multikinase inhibitor, is the only currently approved agent for systemic therapy in patients with advanced stage HCC and early stage liver disease. It has been shown to improve the overall survival, but with various side effects, while its cost is not negligible. Sorafenib has been in the market for a decade and has set the stage for personalized targeted therapy. Its role during this time has ranged from monotherapy to neoadjuvant and adjuvant treatment with surgical resection, liver transplantation and chemoembolization or even in combination with other chemotherapeutic agents. In this review our aim is to highlight in depth the current position of Sorafenib in the armamentarium against HCC and how that has evolved over time in its use either as a single agent or in combination with other therapies.
肝细胞癌（HCC）是全球最常见的恶性疾病之一，在癌症相关死亡率中位列第三。尽管有多种治疗方案可供选择，但根据疾病阶段，只有少数患者有资格接受根治性治疗，因此大多数肝癌患者都接受姑息治疗。索拉非尼是一种多激酶抑制剂，是目前唯一被批准用于晚期HCC和早期肝病患者全身治疗的药物。它已被证明可提高总生存期，但有各种副作用，且成本不可忽视。索拉非尼已上市十年，为个性化靶向治疗奠定了基础。在此期间，其作用范围从单一疗法到与手术切除、肝移植、化疗栓塞甚至与其他化疗药物联合使用的新辅助和辅助治疗。在本综述中，我们的目的是深入强调索拉非尼在对抗HCC的药物库中的当前地位，以及它作为单一药物或与其他疗法联合使用时，其使用方式是如何随时间演变的。
